SIMPLY BETTER BRANDS CORP (SBBC.CA) Stock Fundamental Analysis
TSX-V:SBBC - TSX Venture Exchange - CA82888R1055 - Common Stock - Currency: CAD
We assign a fundamental rating of 2 out of 10 to SBBC. SBBC was compared to 35 industry peers in the Pharmaceuticals industry. SBBC has a bad profitability rating. Also its financial health evaluation is rather negative. SBBC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SBBC has reported negative net income.
In the past year SBBC had a positive cash flow from operations.
In the past 5 years SBBC always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SBBC reported negative operating cash flow in multiple years.
1.2 Ratios
SBBC has a Return On Assets (-1.47%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -22.83%, SBBC is in line with its industry, outperforming 45.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.47% | ||
| ROE | -22.83% | ||
| ROIC | N/A |
ROA(3y)-53.1%
ROA(5y)-47.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SBBC's Gross Margin of 29.78% is in line compared to the rest of the industry. SBBC outperforms 45.71% of its industry peers.
SBBC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SBBC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.17%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SBBC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SBBC has been increased compared to 1 year ago.
The number of shares outstanding for SBBC has been increased compared to 5 years ago.
SBBC has a better debt/assets ratio than last year.
2.2 Solvency
SBBC has an Altman-Z score of -0.57. This is a bad value and indicates that SBBC is not financially healthy and even has some risk of bankruptcy.
SBBC's Altman-Z score of -0.57 is in line compared to the rest of the industry. SBBC outperforms 51.43% of its industry peers.
SBBC has a debt to FCF ratio of 6.61. This is a slightly negative value and a sign of low solvency as SBBC would need 6.61 years to pay back of all of its debts.
SBBC's Debt to FCF ratio of 6.61 is fine compared to the rest of the industry. SBBC outperforms 68.57% of its industry peers.
SBBC has a Debt/Equity ratio of 2.69. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.69, SBBC is doing worse than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.69 | ||
| Debt/FCF | 6.61 | ||
| Altman-Z | -0.57 |
ROIC/WACCN/A
WACC8.56%
2.3 Liquidity
A Current Ratio of 0.90 indicates that SBBC may have some problems paying its short term obligations.
SBBC has a Current ratio of 0.90. This is amonst the worse of the industry: SBBC underperforms 80.00% of its industry peers.
SBBC has a Quick Ratio of 0.90. This is a bad value and indicates that SBBC is not financially healthy enough and could expect problems in meeting its short term obligations.
SBBC has a Quick ratio of 0.74. This is in the lower half of the industry: SBBC underperforms 65.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 98.61% over the past year.
The Revenue for SBBC has decreased by -42.52% in the past year. This is quite bad
SBBC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.58% yearly.
EPS 1Y (TTM)98.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.93%
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y42.58%
Revenue growth 5YN/A
Sales Q2Q%3.75%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 38.79% on average over the next years. This is a very strong growth
EPS Next Y200%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year44.26%
Revenue Next 2Y38.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SBBC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SBBC is valuated rather expensively with a Price/Forward Earnings ratio of 19.12.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SBBC indicates a rather cheap valuation: SBBC is cheaper than 82.86% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.39. SBBC is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.12 |
4.2 Price Multiples
SBBC's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.66 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBBC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:SBBC (6/12/2025, 7:00:00 PM)
0.79
-0.02 (-2.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.34%
Inst Owner ChangeN/A
Ins Owners18.58%
Ins Owner ChangeN/A
Market Cap84.67M
Analysts84
Price Target1.79 (126.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.12 | ||
| P/S | 1.35 | ||
| P/FCF | 54.66 | ||
| P/OCF | 53.71 | ||
| P/B | 37.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.04
Fwd EY5.23%
FCF(TTM)0.01
FCFY1.83%
OCF(TTM)0.01
OCFY1.86%
SpS0.58
BVpS0.02
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.47% | ||
| ROE | -22.83% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.78% | ||
| FCFM | 2.48% |
ROA(3y)-53.1%
ROA(5y)-47.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.17%
GM growth 5YN/A
F-Score5
Asset Turnover1.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.69 | ||
| Debt/FCF | 6.61 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.3% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | -0.57 |
F-Score5
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)2.76%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.93%
EPS Next Y200%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y42.58%
Revenue growth 5YN/A
Sales Q2Q%3.75%
Revenue Next Year44.26%
Revenue Next 2Y38.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y73.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year276.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y133.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y134.46%
OCF growth 3YN/A
OCF growth 5YN/A